Autopsy report · NCT01147393
Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma
Cause of deathSlow enrollment
“closed to enrollment due to slow patient accrual”
Life of this trial
- Registered 4 months before it started.
- Ran for about 4 years 10 months before it stopped.
- 4 participants enrolled.
- Results were posted on the registry 1 year 10 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Weill Medical College of Cornell University
- Sponsor type
- University, hospital or other
- Conditions
- Follicular Lymphoma
- Interventions
- 90Y-epratuzumab tetraxetan; veltuzumab
- Participants
- 4
- Sites
- 1
- Countries
- United States
Trials that died the same way
- A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia
“Closed due to slow enrollment” - Intensity Modulated Radiation Therapy (IMRT) for Patients With Rectal Cancer
“The study was closed to enrollment due to slow accrual.” - Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant
“Study closed due to slow enrollment.” - Use of 3M Cavilon Advanced Skin Protectant in the Management of Damaged Skin Around an Ostomy, Drain or Fistula
“Slow enrollment of patients” - A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
“Study closed to enrollment due to low accrual.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.